Not all investors caught the drift of Ovid Therapeutics Inc.'s phase II data with OV-101 (gaboxadol) in Angelman syndrome (AS), but CEO Jeremy Levin told BioWorld that insiders rejoiced and the company is moving ahead with the delta-selective GABAA receptor agonist.